WisnaPharma

WisnaPharma is a clinical-stage biopharmaceutical company based in Shanghai, China, dedicated to the discovery and development of next-generation small molecule drugs for oncology and autoimmune diseases. The company's primary focus is on the development of highly selective kinase inhibitors, specifically targeting the cyclin-dependent kinase (CDK) family to address unmet needs in cancer treatment. Its lead candidate, WN-101, is a potent CDK4/6 inhibitor currently in clinical trials for breast cancer and other solid tumors. Additionally, WisnaPharma is advancing WN-103, a selective CDK2 inhibitor aimed at overcoming resistance to first-generation CDK4/6 inhibitors. The company leverages a proprietary drug discovery platform to design molecules with improved safety profiles and superior efficacy. Backed by prominent investors like Qiming Venture Partners and Lilly Asia Ventures, WisnaPharma aims to provide innovative therapeutic solutions for patients globally.